| P2093 | author name string | Min Wu | |
| | Qiao Wang | |
| | Xia Zhao | |
| | Hongling Peng | |
| | Xiaorong Qi | |
| P2860 | cites work | An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 |
| | Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function | Q24295164 |
| | Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer | Q24596266 |
| | Targeting folate receptor alpha for cancer treatment | Q26744215 |
| | Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer | Q26780387 |
| | Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer | Q26783551 |
| | The PI3K/AKT Pathway and Renal Cell Carcinoma | Q26800216 |
| | Immune Checkpoint Blockade in Cancer Therapy | Q26830509 |
| | The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges | Q26851852 |
| | A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An | Q27302763 |
| | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 |
| | Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study | Q27851528 |
| | Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 |
| | Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer | Q27852608 |
| | Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study | Q27853070 |
| | Integrated genomic analyses of ovarian carcinoma | Q27860518 |
| | TOR signaling in growth and metabolism | Q27860757 |
| | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 |
| | Untangling the ErbB signalling network | Q27860884 |
| | The deaf and the dumb: the biology of ErbB-2 and ErbB-3 | Q28185247 |
| | Identification of the Anti-proliferative protein Tob as a MAPK substrate | Q28216566 |
| | Invasive growth: a MET-driven genetic programme for cancer and stem cells | Q28253680 |
| | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 |
| | Integrated genomic characterization of endometrial carcinoma | Q28289962 |
| | DNA double-strand break repair: from mechanistic understanding to cancer treatment | Q28293130 |
| | Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions | Q28301685 |
| | Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies | Q29614869 |
| | Trastuzumab--mechanism of action and use in clinical practice | Q29615810 |
| | Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 |
| | Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells | Q29617437 |
| | Angiogenesis as a therapeutic target | Q29619525 |
| | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 |
| | PARP inhibition: PARP1 and beyond | Q29619617 |
| | A renaissance for SRC | Q30014833 |
| | PI3K and cancer: lessons, challenges and opportunities | Q30080017 |
| | A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). | Q30275176 |
| | Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study | Q30407709 |
| | Papillomavirus E6 oncoproteins | Q30410553 |
| | Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study | Q30416923 |
| | Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study | Q30436932 |
| | Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy | Q33316645 |
| | Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer | Q33369818 |
| | Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study | Q33378256 |
| | ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer | Q40443588 |
| | Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line | Q40638581 |
| | Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer | Q41386447 |
| | Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors | Q41468431 |
| | Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors | Q41595492 |
| | Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer | Q41610690 |
| | Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma | Q41691425 |
| | A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors | Q41699326 |
| | GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity | Q42335706 |
| | Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner | Q42347025 |
| | A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer | Q42492202 |
| | Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. | Q42695216 |
| | Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-α-dependent gene expression | Q42838878 |
| | A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). | Q42963970 |
| | Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer | Q42981952 |
| | A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer | Q43003099 |
| | A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. | Q43279004 |
| | A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia | Q43902249 |
| | Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition | Q44048055 |
| | Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 |
| | Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways | Q44127144 |
| | Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie | Q44208606 |
| | Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). | Q44324783 |
| | Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. | Q44327930 |
| | Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice | Q44522454 |
| | Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 |
| | Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation | Q44665734 |
| | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Q44846367 |
| | siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity | Q44933975 |
| | A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer | Q45000539 |
| | Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 |
| | Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. | Q46029695 |
| | A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia | Q46078145 |
| | A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer | Q46110704 |
| | Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma | Q46170735 |
| | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial | Q46270437 |
| | Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. | Q46470854 |
| | Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study | Q46630310 |
| | Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer | Q46753331 |
| | Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. | Q46871150 |
| | A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer | Q46916475 |
| | A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma | Q46944458 |
| | A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer | Q47130538 |
| | BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer | Q47164964 |
| | Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial | Q47306372 |
| | ATR/CHK1 inhibitors and cancer therapy | Q47622968 |
| | A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer | Q47861842 |
| | Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecologi | Q48110100 |
| | Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. | Q48234647 |
| | Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative | Q49158742 |
| | SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab‑resistant ovarian cancer model | Q49358317 |
| | Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer | Q49678489 |
| | A phase II study of apatinib in patients with recurrent epithelial ovarian cancer | Q49724049 |
| | Rational Design for Cervical Cancer Therapeutics: Cellular and Non-Cellular Based Strategies on the Horizon for Recurrent, Metastatic or Refractory Cervical Cancer. | Q49797507 |
| | Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. | Q35999582 |
| | Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours | Q36027042 |
| | BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group | Q36145443 |
| | JAK/STAT/SOCS-signaling pathway and colon and rectal cancer | Q36199003 |
| | A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer | Q36214463 |
| | Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. | Q36245116 |
| | A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. | Q36274386 |
| | Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Q36287626 |
| | Epidermal growth factor receptor (EGFR) signaling in cancer | Q36353031 |
| | The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions | Q36360691 |
| | ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up | Q36372293 |
| | NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer | Q36387267 |
| | A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial | Q36407018 |
| | Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer | Q36456386 |
| | A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). | Q36480124 |
| | The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability | Q36602569 |
| | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 |
| | Triage of HPV positive women in cervical cancer screening | Q36679896 |
| | Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. | Q36746785 |
| | The development of PARP inhibitors in ovarian cancer: from bench to bedside | Q36752056 |
| | Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study | Q36768921 |
| | A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met | Q36777999 |
| | OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 |
| | Therapeutic applications of PARP inhibitors: anticancer therapy and beyond | Q36853236 |
| | PD-1 and PD-1 ligands: from discovery to clinical application | Q36868261 |
| | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | Q36932216 |
| | Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors | Q36939783 |
| | Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer | Q36941966 |
| | PI3K pathway dependencies in endometrioid endometrial cancer cell lines | Q36980561 |
| | HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer | Q37080967 |
| | Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study | Q37130150 |
| | CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer | Q37173597 |
| | Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy | Q37193459 |
| | Class I Phosphoinositide 3-Kinase /p110α and /p110β Isoforms in Endometrial Cancer | Q60909474 |
| | OCT4 accelerates tumorigenesis through activating JAK/STAT signaling in ovarian cancer side population cells | Q60927312 |
| | Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial | Q64109213 |
| | A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254) | Q64124105 |
| | Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials | Q64236616 |
| | Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review | Q64248066 |
| | An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. | Q64889817 |
| | Increasing Antitumor Activity of JAK Inhibitor by Simultaneous Blocking Multiple Survival Signaling Pathways in Human Ovarian Cancer. | Q64897069 |
| | Epithelial to Mesenchymal Transition and Cell Biology of Molecular Regulation in Endometrial Carcinogenesis. | Q64964271 |
| | Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. | Q64979612 |
| | Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas | Q72998611 |
| | Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 |
| | Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6) | Q79426026 |
| | Her-2/neu overexpression and amplification in uterine papillary serous carcinoma | Q80396741 |
| | Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer | Q83069293 |
| | Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer | Q83419009 |
| | Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient | Q83818621 |
| | Structural biology: Porthole to catalysis | Q84372712 |
| | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study | Q84491268 |
| | Hormone receptors as a marker of poor survival in epithelial ovarian cancer | Q85478789 |
| | State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer | Q85579065 |
| | Endometrial cancer | Q86100370 |
| | A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer | Q87356244 |
| | Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer | Q87424383 |
| | Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial | Q87460208 |
| | Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial | Q88123697 |
| | Ovarian cancer | Q88195269 |
| | Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial | Q88310077 |
| | Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001) | Q88607647 |
| | Latest clinical evidence and further development of PARP inhibitors in ovarian cancer | Q88639836 |
| | Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor | Q89223938 |
| | Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells | Q89355308 |
| | Lenvatinib in Management of Solid Tumors | Q89647095 |
| | Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers | Q89998161 |
| | Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer | Q90098861 |
| | Targeting of host cell receptor tyrosine kinases by intracellular pathogens | Q90148927 |
| | Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance | Q90276196 |
| | Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer | Q90281739 |
| | Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028 | Q90314007 |
| | Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | Q90342379 |
| | Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer | Q90342385 |
| | Progress in the treatment of solid tumors with apatinib: a systematic review | Q90529019 |
| | Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer | Q90622515 |
| | Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers | Q90661141 |
| | Lapatinib | Q90704219 |
| | Gefitinib | Q90704283 |
| | Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment | Q90737531 |
| | A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study | Q90763649 |
| | Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study | Q90778927 |
| | Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study | Q90783657 |
| | Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. | Q37193617 |
| | The papillomavirus E7 proteins | Q37198662 |
| | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia | Q37235598 |
| | A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study | Q37294922 |
| | A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma | Q37432527 |
| | Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models | Q37447340 |
| | Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study | Q37529822 |
| | A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study | Q37677618 |
| | Epidemiology of ovarian cancer: a review | Q37720438 |
| | Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study | Q37809370 |
| | MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 |
| | The angiogenic process as a therapeutic target in cancer | Q37850516 |
| | Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials | Q37953161 |
| | The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer | Q38053414 |
| | Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy | Q38087230 |
| | Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study | Q38127164 |
| | Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis. | Q38140940 |
| | A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia | Q38387402 |
| | Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. | Q38387666 |
| | Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma | Q38388678 |
| | Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. | Q38393818 |
| | Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). | Q38396745 |
| | Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q38406496 |
| | Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer | Q38419271 |
| | Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer | Q38441379 |
| | Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival | Q38441644 |
| | Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma | Q38528349 |
| | Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. | Q38631649 |
| | A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE. | Q38644521 |
| | Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). | Q38653061 |
| | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial | Q38654552 |
| | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study | Q38669565 |
| | Development of PARP inhibitors in gynecological malignancies. | Q38674502 |
| | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression | Q38704805 |
| | Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo | Q38708134 |
| | Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial | Q33383385 |
| | Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma | Q33395016 |
| | Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer | Q33407093 |
| | Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer | Q33408279 |
| | A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer | Q33408735 |
| | The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial | Q33408750 |
| | Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer | Q33410174 |
| | Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer | Q33410746 |
| | A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer | Q33415805 |
| | Incorporation of pazopanib in maintenance therapy of ovarian cancer | Q33417673 |
| | A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis | Q33418461 |
| | A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study | Q33419816 |
| | Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial | Q33427744 |
| | Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer | Q33435836 |
| | Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study | Q33437373 |
| | Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months | Q33437774 |
| | A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours | Q33439527 |
| | Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers | Q33439705 |
| | Trastuzumab emtansine: mechanisms of action and drug resistance | Q33759627 |
| | Prognostic roles of Notch receptor mRNA expression in human ovarian cancer | Q33779227 |
| | Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment | Q33794185 |
| | A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFα-TGFα-EGFR | Q33835932 |
| | A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 |
| | Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. | Q34099883 |
| | Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34121226 |
| | Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. | Q34147360 |
| | Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors | Q34152009 |
| | Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. | Q34422265 |
| | The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 |
| | Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. | Q34520190 |
| | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 |
| | Growing knowledge of the mTOR signaling network | Q34620724 |
| | Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein | Q34717857 |
| | Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer | Q90857957 |
| | Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer | Q90863443 |
| | Endocrine therapy in endometrial cancer: An old dog with new tricks | Q90927597 |
| | Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review | Q90957632 |
| | Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial | Q91027526 |
| | Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial | Q91068249 |
| | Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer | Q91100206 |
| | Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study | Q91275584 |
| | Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial | Q91465884 |
| | Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer | Q91500865 |
| | Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study | Q91694228 |
| | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Q91700806 |
| | Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer | Q91719723 |
| | Raf-ERK1/2 signalling pathways mediate steroid hormone synthesis in bovine ovarian granulosa cells | Q91746067 |
| | Mechanisms of PARP inhibitor resistance in ovarian cancer | Q91799184 |
| | Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51 | Q92051015 |
| | Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | Q92086589 |
| | Combining PARP inhibition with PD-1 inhibitors | Q92395353 |
| | Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial | Q92395369 |
| | Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) | Q92560472 |
| | Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial | Q92606752 |
| | 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial | Q92614348 |
| | Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer | Q92667885 |
| | Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial | Q92684130 |
| | Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer | Q92726174 |
| | Antibody-drug conjugates in gynecologic malignancies | Q92726180 |
| | Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers | Q92780877 |
| | Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors | Q92801272 |
| | Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study | Q92820087 |
| | Treatment of recurrent epithelial ovarian cancer | Q92847059 |
| | Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial | Q92857990 |
| | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial | Q92905904 |
| | Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimens | Q93000430 |
| | Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial | Q93043588 |
| | The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer | Q93063820 |
| | Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial | Q93121862 |
| | Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma | Q93160975 |
| | Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis. | Q34768853 |
| | A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. | Q34781699 |
| | Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer | Q34781970 |
| | Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study | Q34850394 |
| | Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study | Q35023418 |
| | Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma | Q35139055 |
| | Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma | Q35144264 |
| | Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study | Q35154219 |
| | Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group | Q35172203 |
| | A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study | Q35180428 |
| | Src family kinases and paclitaxel sensitivity | Q35214722 |
| | A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study | Q35216723 |
| | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute | Q35602123 |
| | Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody | Q35604097 |
| | Phosphatidylinositol-3-kinase as a therapeutic target in melanoma | Q35606261 |
| | A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study | Q35747034 |
| | A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study | Q35748507 |
| | Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. | Q35895214 |
| | Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update | Q35904534 |
| | Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. | Q35913613 |
| | A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors | Q49881127 |
| | Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial | Q49975220 |
| | HER kinase inhibition in patients with HER2- and HER3-mutant cancers | Q50115014 |
| | Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. | Q50564383 |
| | Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute. | Q50591367 |
| | Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. | Q50664932 |
| | Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. | Q50684803 |
| | Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer. | Q50696151 |
| | A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. | Q50964092 |
| | Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. | Q50981985 |
| | Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition. | Q51006519 |
| | A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. | Q51065459 |
| | A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models. | Q51110603 |
| | Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. | Q51576159 |
| | A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. | Q52611153 |
| | A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. | Q52628568 |
| | Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis. | Q52763151 |
| | The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer. | Q52799875 |
| | HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. | Q52808198 |
| | A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. | Q52839148 |
| | Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. | Q52867263 |
| | PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer. | Q52955313 |
| | Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. | Q53093760 |
| | Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). | Q53177591 |
| | Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. | Q53668957 |
| | A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). | Q53673760 |
| | Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. | Q54326161 |
| | A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo | Q54526385 |
| | Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. | Q54566293 |
| | A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. | Q54656439 |
| | PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. | Q55004657 |
| | Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. | Q55005815 |
| | RAS oncogenes: the first 30 years. | Q55036584 |
| | Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. | Q55070567 |
| | Targeting ERBB2 mutations in solid tumors: biological and clinical implications. | Q55512723 |
| | Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation | Q56240758 |
| | A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer | Q56516705 |
| | Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 |
| | Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial | Q56957787 |
| | Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial | Q56967070 |
| | Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised | Q57173042 |
| | A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Onco | Q57181489 |
| | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | Q57806929 |
| | Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer | Q58549061 |
| | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial | Q58599459 |
| | Antiangiogenic therapy in oncology: current status and future directions | Q38725587 |
| | Regulation of epithelial-mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs | Q38726364 |
| | Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K/Akt pathways | Q38728396 |
| | Blocking NOTCH Pathway can Enhance the Effect of EGFR Inhibitor through Targeting CD133+ Endometrial Cancer Cells | Q38735642 |
| | Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib | Q38742492 |
| | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q38743961 |
| | Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes | Q38757645 |
| | Notch and TGFβ form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells | Q38778435 |
| | Treatment strategies for endometrial cancer: current practice and perspective. | Q38784346 |
| | α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer | Q38793227 |
| | Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study | Q38794249 |
| | VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients | Q38805626 |
| | Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial | Q38822258 |
| | Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). | Q38857412 |
| | Antibody-drug conjugates for cancer therapy. | Q38864720 |
| | Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial | Q38879397 |
| | PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer. | Q38882236 |
| | IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors | Q38883288 |
| | A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors | Q38926282 |
| | Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway | Q38937086 |
| | Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing | Q38968504 |
| | The role of fulvestrant in endometrial cancer | Q38970776 |
| | Clinical Pharmacokinetics and Pharmacodynamics of Cediranib | Q39036230 |
| | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. | Q39138428 |
| | Tumor angiogenesis and vascular normalization: alternative therapeutic targets | Q39403862 |
| | Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study | Q39499020 |
| | Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. | Q39620425 |
| | Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety | Q39933788 |
| | Involvement of a JAK/STAT pathway inhibitor: cytokine inducible SH2 containing protein in breast cancer | Q39979699 |
| | Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction | Q39991776 |
| | ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models | Q40138516 |
| | Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. | Q40434632 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P433 | issue | 1 | |
| P921 | main subject | female reproductive system neoplasm | Q56014489 |
| P304 | page(s) | 137 | |
| P577 | publication date | 2020-07-29 | |
| P1433 | published in | Signal Transduction and Targeted Therapy | Q108821959 |
| P1476 | title | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence | |
| P478 | volume | 5 | |